Daridorexant
Indication
Treating long-term insomnia (NICE TA922)
Green (Restricted)
Brand:
Quviviq
Nice TA:
922
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Central nervous system
Background
1.1 Daridorexant is recommended for treating insomnia in adults with symptoms lasting for 3 nights or more per week for at least 3 months, and whose daytime functioning is considerably affected, only if:
- cognitive behavioural therapy for insomnia (CBTi) has been tried but not worked, or
- CBTi is not available or is unsuitable.
Recommendation
LSCMMG Recommendation:
Green (Restricted)
Reason for decision:
Suitable for initiation in primary care in line with restrictions
Supporting documents: